Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan

Journal of the Formosan Medical Association

Volumn 105, Issue 9, 2006, Pages 708-714

  Hsu, Jeng Yuan ^a,b   Perng, Reury Perng ^c   Lu, Jau Yeong ^d   Wu, Chin Pyng ^e   Huang, Ming Shyan ^f   Luh, Kwen Tay ^g   Yang, Pan Chyr ^g  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; HandiHaler; Ipratropium; Metered dose inhaler; Tiotropium

Indexed keywords

FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MASS SCREENING; METERED DOSE INHALER; MULTICENTER STUDY; PARALLEL DESIGN; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; URINARY FREQUENCY;

EID: 33749345328     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60198-4     Document Type: Article

References (21)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Chan-Yeung M, Ait-Khaled N, White N, et al. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004;8:2-14.
3. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
4. Guidelines for Chronic Obstructive Pulmonary Disease. Taiwan Society of Pulmonary and Critical Care Medicine, 2003. [in Chinese]
5. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129:856-70.
6. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993;52:521-7.
7. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19:209-16.
8. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289-94.
9. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
10. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Phormacotherapy 2003;23:183-9.
11. Rockville MD. Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART), 5th edition. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 1995.
12. Anzueto A, Tashkin D, Menjoge S, et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18:75-81.
13. Tashkin D, Celli B, Decramer M, et al. Bronchodilator Responsiveness in COPD Patients Enrolled in the UPLIFT Trial. ATS 2005 San Diego International Conference. [Abstract]
14. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
15. Annis P, Landa J, Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 1976;44:74-7.
16. Foster WM, Langenback EG, Glaser ML, et al. Acute effect of ipratropium bromide at therapeutic dose on mucus transport of adult asthmatics. Eur J Respir Dis 1983; 128:(Suppl 2):554-7.
17. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004;125:1726-34.
18. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-65.
19. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163: 1087-92.
20. Dahl R, Greefhorst LA, Nowak D, et al. inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
21. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002;20:1138-46.